rFVIIa is approved for treatment of bleeding in patients who have inherited lack of
clotting factors but is not approved for treatment of ICH.
Participants in the FASTEST research study are placed at random, that is by chance, into one of 2 groups. They have an equal chance of getting rFVIIa or placebo (no active ingredient). One group receives rFVIIa intravenously over 2 minutes within two hours of onset of symptoms and the other group receives placebo. We do not know if rFVIIa is better than placebo for patients with bleeding in the brain.
The results of the FASTEST research study will help doctors discover if rFVIIa improves outcome in patients with bleeding in the brain.
Medical care otherwise will be identical for the two treatment groups, including close management of blood pressure and care within an intensive care unit. Some patients will be enrolled without consent if a family member or representative is not rapidly available.
Before the research study starts, we will consult with the community.